The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers

Affiliations

¹ Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy; Molecular Immunology Unit, Department of Research Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: roberto.ferrara@istitutotumori.mi.it.
² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
⁴ Medical Oncology Department Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Free article

Editorial

Roberto Ferrara et al. J Thorac Oncol. 2023 Jan.

Free article

. 2023 Jan;18(1):17-20.

doi: 10.1016/j.jtho.2022.11.001.

¹ Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy; Molecular Immunology Unit, Department of Research Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: roberto.ferrara@istitutotumori.mi.it.
² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
⁴ Medical Oncology Department Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G. Zhou C, et al. J Thorac Oncol. 2023 Jan;18(1):93-105. doi: 10.1016/j.jtho.2022.09.217. Epub 2022 Sep 29. J Thorac Oncol. 2023. PMID: 36184068 Clinical Trial.